In late-breaking presentations at the American Society of Nephrology Kidney Week meeting and simultaneously published in two ...

Sodium-glucose co-transporter 2 (SGLT2) inhibitors, initially developed to treat type 2 diabetes, have significant heart- and ...

Sodium-glucose co-transporter 2 (SGLT2) inhibitors, initially developed to treat type 2 diabetes, have significant heart- and ...

The results of two large-scale studies demonstrate that sodium-glucose co-transporter 2 (SGLT2) inhibitors significantly ...

The SGLT2 inhibitors market is driven by the rising prevalence of diabetes and demand for effective antidiabetic therapies ...

Researchers compared the incidence of infection-related outcomes and hypoglycemia across antidiabetic drug classes in patients with inflammatory arthritis and diabetes.

Sean Virani, MD, lead author of the new guidelines and president of the CCS, explained that the guidelines use the term ...

The market is expanding due to rising cardiovascular disease prevalence, an aging population, and advancements in treatments like SGLT2 inhibitors. Integration of digital health solutions and ...

SGLT2 inhibitors represent one of the most remarkable therapeutic developments in heart failure care, transitioning from ...

SGLT2 inhibitors are one of many medicines you may take to treat type 2 diabetes. They also can protect your kidneys and make heart failure less likely. (Photo Credit: Moment RF/Getty Images) SGLT2 ...

Please provide your email address to receive an email when new articles are posted on . SGLT2 inhibitors vs. other agents were tied to a slower eGFR decline for adults with ADPKD and type 2 diabetes.